Home › Funds › Venrock Adviser, LLC › SYRE
Venrock Adviser, LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Venrock Adviser, LLC reported holding 2,485,448 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$221.3M, representing 10.75% of its reported portfolio and ranking #3 among its reported holdings. Venrock Adviser, LLC has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's SYRE position evolved
Venrock Adviser, LLC first disclosed a stake in SYRE in Q4 2023 at 2,372,714 shares (US$51.1M). The position peaked in Q2 2026 at 2,985,448 shares, worth US$265.0M. Across 12 filings, Venrock Adviser, LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,485,448 shares valued at US$221.3M — a reduction of -500,000 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2025 (shares rose 54% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 2.37M | $51.06M | New |
| Q1 2024 | 2.17M | $82.38M | Reduce |
| Q2 2024 | 2.69M | $63.13M | Add |
| Q3 2024 | 2.69M | $78.98M | Hold |
| Q4 2024 | 2.69M | $62.52M | Hold |
| Q1 2025 | 2.69M | $43.33M | Hold |
| Q2 2025 | 2.69M | $40.20M | Hold |
| Q3 2025 | 2.69M | $45.01M | Hold |
| Q4 2025 | 3.69M | $120.74M | Add |
| Q1 2026 | 3.69M | $185.89M | Hold |
| Q2 2026 | 2.99M | $265.05M | Reduce |
| Q3 2026 | 2.49M | $221.28M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 68 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- Paradigm Biocapital Advisors LP 4.46M sh · $396.85M · Q3 2026
- RTW INVESTMENTS, LP 3.69M sh · $328.68M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.20M sh · $309.04M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M sh · $245.76M · Q3 2026
- TCG Crossover Management, LLC 1.90M sh · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $168.46M · Q3 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- BRAIDWELL LP 713.96K sh · $63.56M · Q3 2026
- Commodore Capital LP 700.00K sh · $62.32M · Q3 2026
- a16z Capital Management, L.L.C. 3.08M sh · $56.74M · Q3 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held SYRE?
Venrock Adviser, LLC has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Venrock Adviser, LLC's current position in SYRE?
As of Q3 2026, Venrock Adviser, LLC holds 2.49M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $221.28M, representing 10.75% of its reported portfolio and ranking #3.
Has Venrock Adviser, LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Venrock Adviser, LLC reduced its position in SYRE. The position peaked in Q2 2026 at 2.99M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.